Business Description
PMV Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
8 Clarke Drive, Suite 3, Cranbury, NJ, USA, 08512
Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 22.03 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | 0 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -29.3 | |||||
3-Year EPS without NRI Growth Rate | -31.6 | |||||
3-Year FCF Growth Rate | -28.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59 | |||||
9-Day RSI | 58.25 | |||||
14-Day RSI | 57.38 | |||||
6-1 Month Momentum % | -0.49 | |||||
12-1 Month Momentum % | -52.57 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 24.76 | |||||
Quick Ratio | 24.76 | |||||
Cash Ratio | 24.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.3 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -22.44 | |||||
ROA % | -20.98 | |||||
ROIC % | -226.44 | |||||
ROC (Joel Greenblatt) % | -498.14 | |||||
ROCE % | -21.95 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.78 | |||||
Price-to-Tangible-Book | 2.78 | |||||
EV-to-EBIT | -7.22 | |||||
EV-to-EBITDA | -7.26 | |||||
EV-to-FCF | -8.28 | |||||
Price-to-Net-Current-Asset-Value | 2.99 | |||||
Price-to-Net-Cash | 3.04 | |||||
Earnings Yield (Greenblatt) % | -13.85 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:PMVP
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -1.52 | ||
Beta | 0 | ||
Volatility % | 66.35 | ||
14-Day RSI | 57.38 | ||
14-Day ATR ($) | 1.333155 | ||
20-Day SMA ($) | 15.466 | ||
12-1 Month Momentum % | -52.57 | ||
52-Week Range ($) | 8.99 - 35.14 | ||
Shares Outstanding (Mil) | 45.62 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
PMV Pharmaceuticals Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |